Regeneron Pharmaceuticals, Inc. (FRA:RGO)

Market Cap	64.03B -12.9%
Revenue (ttm)	12.22B +1.0%
Net Income	3.84B +2.1%
EPS	35.33 +8.2%
Shares Out	n/a
PE Ratio	16.69
Forward PE	15.61
Dividend	3.14 (0.49%)
Ex-Dividend Date	Nov 20, 2025

Volume	3
Average Volume	15
Open	636.80
Previous Close	649.80
Day's Range	636.80 - 641.60
52-Week Range	420.00 - 705.00
Beta	n/a
RSI	47.30
Earnings Date	Jan 30, 2026

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous sq...

• Industry: Pharmaceutical Preparations
• Founded: 1988
• Employees: 15,222
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: RGO

Financial Performance

In 2025, Regeneron Pharmaceuticals's revenue was $14.34 billion, an increase of 0.99% compared to the previous year's $14.20 billion. Earnings were $4.50 billion, an increase of 2.09%.

Financial numbers in USD